Top

Published in:

Open Access 01-12-2023 | Coronary Heart Disease | Research

Relationship between the circulating N-terminal pro B-type natriuretic peptide and the risk of carotid artery plaque in different glucose metabolic states in patients with coronary heart disease: a CSCD-TCM ^plus study in China

Authors: Tong Yang, Hongmei Zheng, Guangwei Pan, Ruiying Guo, Fengmin Liu, Shengyuan Liu, Shuang Tao, Lin Li, Rongrong Yang, Chunquan Yu

Published in: Cardiovascular Diabetology | Issue 1/2023

Abstract

Objective

Circulating N-terminal pro B-type natriuretic peptide (NT-proBNP) is a marker for heart failure in patients with coronary heart disease (CHD) and associated with glycemic abnormalities. Studies on the association and diagnostic value of NT-proBNP in carotid plaques (CAP) in patients with CHD are limited.

Methods

The relationships between NT-proBNP and the risk of CAP in different glucose metabolic states, sexes, and age categories were also examined using 5,093 patients diagnosed with CHD. The NT-proBNP tertiles were used to divide patients into three groups in which the NT-proBNP levels, blood glucose levels, the occurrence of CAP, and the number and nature of CAP were measured using normoglycemic (NG), prediabetes (Pre-DM), and diabetes mellitus (DM) glucose metabolic statuses. Logistic regression analyses were used to compare the relationship between NT-proBNP and the risk of CAP occurrence and the number and nature of CAP. The diagnostic value of NT-proBNP for CAP risk was measured using receiver operating characteristic (ROC) curves.

Results

We found a 37% relative increase in the correlation between changes in NT-proBNP per standard deviation (SD) and the incidence of CAP. After adjusting for potential confounders, NT-proBNP at the T3 level was found to be associated with an increased CAP odds ratio (OR) when T1 was used as the reference. This relationship was also present in males, patients aged > 60 years, or both pre-DM and DM states. NT-proBNP was more likely to present as hypoechoic plaques at T1 and as mixed plaques at T3. We also measured the diagnostic accuracy of CAP for NT-proBNP in patients with CHD, with an AUC value of 0.627(95% CI 0.592–0.631), sensitivity of 50.7%, and specificity of 68.0%.

Conclusion

An increase in NT-proBNP was significantly associated with the risk of CAP in patients with CHD, especially in males and patients aged > 60 years, and exhibited specific characteristics under different glucose metabolism states.

Trial registration The study was approved by the Ethics Committee of Tianjin University of Traditional Chinese Medicine (Approval number TJUTCM-EC20210007) and certified by the Chinese Clinical Trials Registry on April 4, 2022 (Registration number ChiCTR2200058296) and March 25, 2022 by ClinicalTrials.gov (registration number NCT05309343).

Graphical Abstract

Available only for authorised users

Virani SS, Newby LK, Arnold SV, Bittner V, Brewer LC, Demeter SH, Dixon DL, Fearon WF, Hess B, Johnson HM, Kazi DS, Kolte D, Kumbhani DJ, LoFaso J, Mahtta D, Mark DB, Minissian M, Navar AM, Patel AR, Piano MR, Rodriguez F, Talbot AW, Taqueti VR, Thomas RJ, van Diepen S, Wiggins B, Williams MS. AHA/ACC/ACCP/ASPC/NLA/PCNA guideline for the management of patients with chronic coronary disease: a report of the American Heart Association/American college of cardiology joint committee on clinical practice guidelines. Circulation. 2023. https://doi.org/10.1161/CIR.0000000000001168.CrossRefPubMed

Theofilis P, Oikonomou E, Chasikidis C, Tsioufis K, Tousoulis D. Pathophysiology of acute coronary syndromes-diagnostic and treatment considerations. Life (Basel). 2023;13(7):1543. https://doi.org/10.3390/life13071543.CrossRefPubMed

El-Andari R, Bozso SJ, Fialka NM, Kang JJH, Nagendran J, Nagendran J. Coronary revascularization for patients with diabetes mellitus: a contemporary systematic review and meta-analysis. Ann Surg. 2022;275(6):1058–66. https://doi.org/10.1097/SLA.0000000000005391.CrossRefPubMed

Xu W, Tian M, Zhou Y. The relationship between insulin resistance, adiponectin and C-reactive protein and vascular endothelial injury in diabetic patients with coronary heart disease. Exp Ther Med. 2018;16(3):2022–6. https://doi.org/10.3892/etm.2018.6407.CrossRefPubMedPubMedCentral

Mehta A, Rigdon J, Tattersall MC, et al. Association of carotid artery plaque with cardiovascular events and incident coronary artery calcium in individuals with absent coronary calcification: the MESA. Circ Cardiovasc Imaging. 2021;14: e011701.CrossRefPubMed

Polak JF, Tracy R, Harrington A, Zavodni AE, O’Leary DH. Carotid artery plaque and progression of coronary artery calcium: the multi-ethnic study of atherosclerosis. J Am Soc Echocardiogr. 2013;26(5):548–55. https://doi.org/10.1016/j.echo.2013.02.009.CrossRefPubMedPubMedCentral

Xu R, Zhang T, Wan Y, Fan Z, Gao X. Prospective study of hemoglobin A1c and incident carotid artery plaque in Chinese adults without diabetes. Cardiovasc Diabetol. 2019;18(1):153. https://doi.org/10.1186/s12933-019-0963-5.CrossRefPubMedPubMedCentral

Oremus M, McKelvie R, Don-Wauchope A, Santaguida PL, Ali U, Balion C, Hill S, Booth R, Brown JA, Bustamam A, Sohel N, Raina P. A systematic review of BNP and NT-proBNP in the management of heart failure: overview and methods. Heart Fail Rev. 2014;19(4):413–9. https://doi.org/10.1007/s10741-014-9440-0. (Erratum.In:HeartFailRev.2014Aug;19(4):565).CrossRefPubMed

Wijkman MO, Claggett BL, Malachias MVB, Vaduganathan M, Ballantyne CM, Kitzman DW, Mosley T, Matsushita K, Solomon SD, Pfeffer MA. Importance of NT-proBNP and conventional risk factors for prediction of death in older adults with and without diabetes mellitus—a report from the Atherosclerosis Risk in Communities (ARIC) study. Diabetes Res Clin Pract. 2022;194: 110164. https://doi.org/10.1016/j.diabres.2022.110164.CrossRefPubMed

10.

Birukov A, Eichelmann F, Kuxhaus O, Polemiti E, Fritsche A, Wirth J, Boeing H, Weikert C, Schulze MB. Opposing associations of NT-proBNP with risks of diabetes and diabetes-related complications. Diabetes Care. 2020;43(12):2930–7. https://doi.org/10.2337/dc20-0553.CrossRefPubMedPubMedCentral

11.

Welsh P, Woodward M, Hillis GS, Li Q, Marre M, Williams B, Poulter N, Ryan L, Harrap S, Patel A, Chalmers J, Sattar N. Do cardiac biomarkers NT-proBNP and hsTnT predict microvascular events in patients with type 2 diabetes? Results from the ADVANCE trial. Diabetes Care. 2014;37(8):2202–10. https://doi.org/10.2337/dc13-2625.CrossRefPubMed

12.

Liu Y, Zhu Y, Jia W, Sun D, Zhao L, Zhang C, Wang C, Chen G, Fu S, Bo Y, Xing Y. Association between lipid profiles and presence of carotid plaque. Sci Rep. 2019;9(1):18011. https://doi.org/10.1038/s41598-019-54285-w.CrossRefPubMedPubMedCentral

13.

Li Z, He Y, Wang S, Li L, Yang R, Liu Y, Cheng Q, Yu L, Zheng Y, Zheng H, Gao S, Yu C. Association between triglyceride glucose index and carotid artery plaque in different glucose metabolic states in patients with coronary heart disease: a RCSCD-TCM study in China. Cardiovasc Diabetol. 2022;21(1):38. https://doi.org/10.1186/s12933-022-01470-3.CrossRefPubMedPubMedCentral

14.

Barua RS, Rigotti NA, Benowitz NL, Cummings KM, Jazayeri MA, Morris PB, Ratchford EV, Sarna L, Stecker EC, Wiggins BS. 2018 ACC expert consensus decision pathway on tobacco cessation treatment: a report of the American college of cardiology task force on clinical expert consensus documents. J Am Coll Cardiol. 2018;72(25):3332–65. https://doi.org/10.1016/j.jacc.2018.10.027.CrossRefPubMed

15.

Ng R, Sutradhar R, Yao Z, Wodchis WP, Rosella LC. Smoking, drinking, diet and physical activity-modifiable lifestyle risk factors and their associations with age to first chronic disease. Int J Epidemiol. 2020;49(1):113–30. https://doi.org/10.1093/ije/dyz078.CrossRefPubMed

16.

Al-Makki A, DiPette D, Whelton PK, Murad MH, Mustafa RA, Acharya S, Beheiry HM, Champagne B, Connell K, Cooney MT, Ezeigwe N, Gaziano TA, Gidio A, Lopez-Jaramillo P, Khan UI, Kumarapeli V, Moran AE, Silwimba MM, Rayner B, Sukonthasan A, Yu J, Saraffzadegan N, Reddy KS, Khan T. Hypertension pharmacological treatment in adults: a world health organization guideline executive summary. Hypertension. 2022;79(1):293–301. https://doi.org/10.1161/HYPERTENSIONAHA.121.18192.CrossRefPubMed

17.

American Diabetes Association. 2. Classification and diagnosis of diabetes: standards of medical care in diabetes—2021. Diabetes Care. 2021;44(1):S15–33. https://doi.org/10.2337/dc21-S002.CrossRef

18.

Li JJ, Zhao SP, Zhao D, Lu GP, Peng DQ, Liu J, Chen ZY, Guo YL, Wu NQ, Yan SK, Wang ZW, Gao RL. 2023 Chinese guideline for lipid management. Front Pharmacol. 2023;29(14):1190934. https://doi.org/10.3389/fphar.2023.1190934.CrossRef

19.

Ma YC, Zuo L, Chen JH, Luo Q, Yu XQ, Li Y, Xu JS, Huang SM, Wang LN, Huang W, Wang M, Xu GB, Wang HY. Modified glomerular filtration rate estimating equation for Chinese patients with chronic kidney disease. J Am Soc Nephrol. 2006;17(10):2937–44. https://doi.org/10.1681/ASN.2006040368. (Erratum in: J Am Soc Nephrol. 2006 Dec;17(12):3540).CrossRefPubMed

20.

Writing Committee Members, Virani SS, Newby LK, Arnold SV, Bittner V, Brewer LC, Demeter SH, Dixon DL, Fearon WF, Hess B, Johnson HM, Kazi DS, Kolte D, Kumbhani DJ, LoFaso J, Mahtta D, Mark DB, Minissian M, Navar AM, Patel AR, Piano MR, Rodriguez F, Talbot AW, Taqueti VR, Thomas RJ, van Diepen S, Wiggins B, Williams MS. 2023 AHA/ACC/ACCP/ASPC/NLA/PCNA guideline for the management of patients with chronic coronary disease: a report of the American Heart Association/American college of cardiology joint committee on clinical practice guidelines. J Am Coll Cardiol. 2023;82(9):833–955. https://doi.org/10.1016/j.jacc.2023.04.003.CrossRef

21.

Malachias MVB, Wijkman MO, Bertoluci MC. NT-proBNP as a predictor of death and cardiovascular events in patients with type 2 diabetes. Diabetol Metab Syndr. 2022;14(1):64. https://doi.org/10.1186/s13098-022-00837-6.CrossRefPubMedPubMedCentral

22.

Pandey KN. Molecular signaling mechanisms and function of natriuretic peptide receptor-A in the pathophysiology of cardiovascular homeostasis. Front Physiol. 2021;19(12): 693099. https://doi.org/10.3389/fphys.2021.693099.CrossRef

23.

Natriuretic Peptides Studies Collaboration, Willeit P, Kaptoge S, Welsh P, Butterworth AS, Chowdhury R, Spackman SA, Pennells L, Gao P, Burgess S, Freitag DF, Sweeting M, Wood AM, Cook NR, Judd S, Trompet S, Nambi V, Olsen MH, Everett BM, Kee F, Ärnlöv J, Salomaa V, Levy D, Kauhanen J, Laukkanen JA, Kavousi M, Ninomiya T, Casas JP, Daniels LB, Lind L, Kistorp CN, Rosenberg J, Mueller T, Rubattu S, Panagiotakos DB, Franco OH, de Lemos JA, Luchner A, Kizer JR, Kiechl S, Salonen JT, Goya Wannamethee S, de Boer RA, Nordestgaard BG, Andersson J, Jørgensen T, Melander O, Ballantyne ChM, DeFilippi Ch, Ridker PM, Cushman M, Rosamond WD, Thompson SG, Gudnason V, Sattar N, Danesh J, Di Angelantonio E. Natriuretic peptides and integrated risk assessment for cardiovascular disease: an individual-participant-data meta-analysis. Lancet Diabetes Endocrinol. 2016;4(10):840–9. https://doi.org/10.1016/S2213-8587(16)30196-6.CrossRefPubMedPubMedCentral

24.

Kerkelä R, Ulvila J, Magga J. Natriuretic peptides in the regulation of cardiovascular physiology and metabolic events. J Am Heart Assoc. 2015;4(10): e002423. https://doi.org/10.1161/JAHA.115.002423.CrossRefPubMedPubMedCentral

25.

Liu HH, Cao YX, Jin JL, Guo YL, Zhu CG, Wu NQ, Gao Y, Zhang Y, Xu RX, Dong Q, Li JJ. Prognostic value of NT-proBNP in patients with chronic coronary syndrome and normal left ventricular systolic function according to glucose status: a prospective cohort study. Cardiovasc Diabetol. 2021;20(1):84. https://doi.org/10.1186/s12933-021-01271-0.CrossRefPubMedPubMedCentral

26.

Gupta DK, Wang TJ. Natriuretic peptides and cardiometabolic health. Circ J. 2015;79(8):1647–55. https://doi.org/10.1253/circj.CJ-15-0589.CrossRefPubMedPubMedCentral

27.

Costa MA, Arranz CT. New aspects of the interactions between the cardiovascular nitric oxide system and natriuretic peptides. Biochem Biophys Res Commun. 2011;406(2):161–4. https://doi.org/10.1016/j.bbrc.2011.02.044.CrossRefPubMed

28.

Del Ry S, Andreassi MG, Clerico A, Biagini A, Giannessi D. Endothelin-1, endothelin-1 receptors and cardiac natriuretic peptides in failing human heart. Life Sci. 2001;68(24):2715–30. https://doi.org/10.1016/s0024-3205(01)01076-1.CrossRefPubMed

29.

Cosson E, Nguyen MT, Pham I, Pontet M, Nitenberg A, Valensi P. N-terminal pro-B-type natriuretic peptide: an independent marker for coronary artery disease in asymptomatic diabetic patients. Diabet Med. 2009;26(9):872–9. https://doi.org/10.1111/j.1464-5491.2009.02788.x.CrossRefPubMed

30.

Cosentino F, Grant PJ, Aboyans V, Bailey CJ, Ceriello A, Delgado V, Federici M, Filippatos G, Grobbee DE, Hansen TB, Huikuri HV, Johansson I, Jüni P, Lettino M, Marx N, Mellbin LG, Östgren CJ, Rocca B, Roffi M, Sattar N, Seferović PM, Sousa-Uva M, Valensi P, Wheeler DC. 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. Eur Heart J. 2020;41(2):255–323. https://doi.org/10.1093/eurheartj/ehz486. (Erratum. In: Eur Heart J. 2020 Dec 1;41(45):4317).CrossRefPubMed

31.

Liu HH, Cao YX, Li S, Guo YL, Zhu CG, Wu NQ, Gao Y, Dong QT, Zhao X, Zhang Y, Sun D, Li JJ. Impacts of prediabetes mellitus alone or plus hypertension on the coronary severity and cardiovascular outcomes. Hypertension. 2018;71(6):1039–46. https://doi.org/10.1161/HYPERTENSIONAHA.118.11063.CrossRefPubMed

32.

Lazo M, Young JH, Brancati FL, Coresh J, Whelton S, Ndumele CE, Hoogeveen R, Ballantyne CM, Selvin E. NH2-terminal pro-brain natriuretic peptide and risk of diabetes. Diabetes. 2013;62(9):3189–93. https://doi.org/10.2337/db13-0478.CrossRefPubMedPubMedCentral

33.

Redfield MM, Rodeheffer RJ, Jacobsen SJ, Mahoney DW, Bailey KR, Burnett JC Jr. Plasma brain natriuretic peptide concentration: impact of age and gender. J Am Coll Cardiol. 2002;40(5):976–82. https://doi.org/10.1016/s0735-1097(02)02059-4.CrossRefPubMed

34.

Nurmohamed NS, Bom MJ, Jukema RA, de Groot RJ, Driessen RS, van Diemen PA, de Winter RW, Gaillard EL, Sprengers RW, Stroes ESG, Min JK, Earls JP, Cardoso R, Blankstein R, Danad I, Choi AD, Knaapen P. AI-guided quantitative plaque staging predicts long-term cardiovascular outcomes in patients at risk for atherosclerotic CVD. JACC Cardiovasc Imaging. 2023. https://doi.org/10.1016/j.jcmg.2023.05.020.CrossRefPubMed

35.

Föllmer B, Williams MC, Dey D, Arbab-Zadeh A, Maurovich-Horvat P, Volleberg RHJA, Rueckert D, Schnabel JA, Newby DE, Dweck MR, Guagliumi G, Falk V, Vázquez Mézquita AJ, Biavati F, Išgum I, Dewey M. Roadmap on the use of artificial intelligence for imaging of vulnerable atherosclerotic plaque in coronary arteries. Nat Rev Cardiol. 2023. https://doi.org/10.1038/s41569-023-00900-3.CrossRefPubMed

36.

Gan L, Feng C, Liu C, Tian S, Song X, Yang L. Association between serum N-terminal pro-B-type natriuretic peptide levels and characteristics of coronary atherosclerotic plaque detected by coronary computed tomography angiography. Exp Ther Med. 2016;12(2):667–75. https://doi.org/10.3892/etm.2016.3371.CrossRefPubMedPubMedCentral

37.

Salama RH, El-Moniem AE, El-Hefney N, Samor T. N-TerminaL PRO-BNP in Acute Coronary Syndrome Patients with ST Elevation Versus Non ST Elevation in Qassim Region of Saudi Arabia. Int J Health Sci (Qassim). 2011 Jul;5(2):136-45. PMID: 23267291; PMCID: PMC3521832.PubMedPubMedCentral

38.

Min JK, Lin FY, Dunning AM, Delago A, Egan J, Shaw LJ, Berman DS, Callister TQ. Incremental prognostic significance of left ventricular dysfunction to coronary artery disease detection by 64-detector row coronary computed tomographic angiography for the prediction of all-cause mortality: results from a two-centre study of 5330 patients. Eur Heart J. 2010;31(10):1212–9. https://doi.org/10.1093/eurheartj/ehq020.CrossRefPubMed

Title: Relationship between the circulating N-terminal pro B-type natriuretic peptide and the risk of carotid artery plaque in different glucose metabolic states in patients with coronary heart disease: a CSCD-TCM plus study in China
Authors: Tong Yang
Hongmei Zheng
Guangwei Pan
Ruiying Guo
Fengmin Liu
Shengyuan Liu
Shuang Tao
Lin Li
Rongrong Yang
Chunquan Yu
Publication date: 01-12-2023
Publisher: BioMed Central
Keywords: Coronary Heart Disease
Diabetes
Published in: Cardiovascular Diabetology / Issue 1/2023
Electronic ISSN: 1475-2840
DOI: https://doi.org/10.1186/s12933-023-02015-y

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Objective

Methods

Results

Conclusion

Graphical Abstract

Please log in to get access to this content

Other articles of this Issue 1/2023

Cardiovascular risk of metabolically healthy obesity in two european populations: Prevention potential from a metabolomic study

L-Arginine in diabetes: clinical and preclinical evidence

SIRT1 mediates the inhibitory effect of Dapagliflozin on EndMT by inhibiting the acetylation of endothelium Notch1

Correction: The atherogenic index of plasma and carotid atherosclerosis in a community population: a population-based cohort study in China

Effects of dapagliflozin and dapagliflozin-saxagliptin on erythropoiesis, iron and inflammation markers in patients with type 2 diabetes and chronic kidney disease: data from the DELIGHT trial

Ethnic differences in the association between age at diagnosis of diabetes and the risk of cardiovascular complications: a population-based cohort study

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials